These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9357141)

  • 1. Taming TNF: strategies to restrain this proinflammatory cytokine.
    Eigler A; Sinha B; Hartmann G; Endres S
    Immunol Today; 1997 Oct; 18(10):487-92. PubMed ID: 9357141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
    Raza A
    Microsc Res Tech; 2000 Aug; 50(3):229-35. PubMed ID: 10891888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
    Fautrel B; Cherin P
    Rev Med Interne; 2000 Oct; 21(10):872-88. PubMed ID: 11075396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
    Billmeier U; Dieterich W; Neurath MF; Atreya R
    World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
    Feldman M; Taylor P; Paleolog E; Brennan FM; Maini RN
    Transplant Proc; 1998 Dec; 30(8):4126-7. PubMed ID: 9865320
    [No Abstract]   [Full Text] [Related]  

  • 6. Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    Sands BE
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S10-7. PubMed ID: 15580148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Suppression of synthesis of tumor necrosis factor].
    Eigler A; Loher F; Endres S
    Internist (Berl); 2001 Jan; 42(1):28-34. PubMed ID: 11271618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
    Bauditz J; Haemling J; Ortner M; Lochs H; Raedler A; Schreiber S
    Gut; 1997 Apr; 40(4):470-4. PubMed ID: 9176073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and autoimmunity during anti-TNF therapy.
    Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
    Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF Therapy.
    Udalova I; Monaco C; Nanchahal J; Feldmann M
    Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
    Sandborn WJ; Hanauer SB
    Inflamm Bowel Dis; 1999 May; 5(2):119-33. PubMed ID: 10338381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
    Silva LC; Ortigosa LC; Benard G
    Immunotherapy; 2010 Nov; 2(6):817-33. PubMed ID: 21091114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg.
    Brennan FM
    Arthritis Res; 2001; 3(4):211-3; discussion 214-5. PubMed ID: 11438037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New indications for treatment of chronic inflammation by TNF-alpha blockade.
    Reimold AM
    Am J Med Sci; 2003 Feb; 325(2):75-92. PubMed ID: 12589232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.
    Danese S; Pagano N; Angelucci E; Stefanelli T; Repici A; Omodei P; Daperno M; Malesci A
    Curr Med Chem; 2007; 14(14):1489-97. PubMed ID: 17584058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
    Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
    Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy with anti-TNF antibodies in patients with Crohn disease].
    Eigler A; Endres S
    Z Gastroenterol; 1997 Sep; 35(9):899-901. PubMed ID: 9432823
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars in Crohn's disease.
    Scheinberg M
    J Crohns Colitis; 2014 Jul; 8(7):710. PubMed ID: 24365641
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-TNF antibody treatment of Crohn's disease.
    van Deventer SJ
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I114-20. PubMed ID: 10577987
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-TNF agents in Crohn's disease.
    Van Assche G; Rutgeerts P
    Expert Opin Investig Drugs; 2000 Jan; 9(1):103-11. PubMed ID: 11060664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.